Zacks Investment Research Upgrades AEterna Zentaris (AEZS) to “Buy”

AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Tuesday. The brokerage presently has a $2.75 target price on the biopharmaceutical company’s stock. Zacks Investment Research‘s price objective would indicate a potential upside of 33.50% from the stock’s previous close.

According to Zacks, “AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers. “

Separately, ValuEngine cut AEterna Zentaris from a “hold” rating to a “sell” rating in a research report on Friday, August 10th. One analyst has rated the stock with a sell rating and three have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $3.25.

NASDAQ:AEZS opened at $2.06 on Tuesday. AEterna Zentaris has a 52 week low of $1.12 and a 52 week high of $3.25. The company has a market capitalization of $38.96 million, a P/E ratio of -1.53 and a beta of 0.75.

AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last released its quarterly earnings data on Tuesday, November 6th. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.10. AEterna Zentaris had a return on equity of 87.85% and a net margin of 34.40%. The firm had revenue of $0.66 million for the quarter. Analysts expect that AEterna Zentaris will post 0.05 EPS for the current fiscal year.

About AEterna Zentaris

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications.

Recommended Story: Leveraged Buyout (LBO) Explained

Get a free copy of the Zacks research report on AEterna Zentaris (AEZS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with's FREE daily email newsletter.

Leave a Reply